{"pmid":32415419,"title":"Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?","text":["Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?","Hydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020. Interestingly, some reports indicate that this wonder drug may be also beneficial for COVID-19 and accordingly, many clinical trials have begun. Here, we discuss different modes of action (anti-inflammatory, antioxidant, inhibition of endosomal acidification, suppression of angiotensin-converting enzyme 2 or ACE2 glycosylation, etc.) of HCQ that might be responsible for its possible anti-COVID-19 effect. On the other hand, this review also makes an honest attempt to delineate mechanisms (increase in vasoconstriction, inhibition of autophagy, depletion of T cells, etc.) indicating how it may aggravate certain conditions and why caution should be taken before granting widespread repurposing of HCQ for COVID-19. Graphical Abstract.","J Neuroimmune Pharmacol","Pahan, Priyanka","Pahan, Kalipada","32415419"],"abstract":["Hydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020. Interestingly, some reports indicate that this wonder drug may be also beneficial for COVID-19 and accordingly, many clinical trials have begun. Here, we discuss different modes of action (anti-inflammatory, antioxidant, inhibition of endosomal acidification, suppression of angiotensin-converting enzyme 2 or ACE2 glycosylation, etc.) of HCQ that might be responsible for its possible anti-COVID-19 effect. On the other hand, this review also makes an honest attempt to delineate mechanisms (increase in vasoconstriction, inhibition of autophagy, depletion of T cells, etc.) indicating how it may aggravate certain conditions and why caution should be taken before granting widespread repurposing of HCQ for COVID-19. Graphical Abstract."],"journal":"J Neuroimmune Pharmacol","authors":["Pahan, Priyanka","Pahan, Kalipada"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415419","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11481-020-09923-w","keywords":["autophagy","covid-19","hydroxychloroquine","hypertension","inflammation","oxidative stress"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666994545930272768,"score":9.490897,"similar":[{"pmid":32496926,"title":"Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.","text":["Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.","Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.","Postgrad Med","Sun, JingKang","Chen, YuTing","Fan, XiuDe","Wang, XiaoYun","Han, QunYing","Liu, ZhengWen","32496926"],"abstract":["Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies."],"journal":"Postgrad Med","authors":["Sun, JingKang","Chen, YuTing","Fan, XiuDe","Wang, XiaoYun","Han, QunYing","Liu, ZhengWen"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496926","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/00325481.2020.1778982","keywords":["sars-cov-2","antiviral","chloroquine","coronavirus","hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1668712823972167680,"score":252.54007},{"pmid":32450198,"title":"A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.","text":["A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.","The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries' leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing.","Int J Antimicrob Agents","Tripathy, Satyajit","Dassarma, Barsha","Roy, Somenath","Chabalala, Hlupheka","Matsabisa, Motlalepula Gilbert","32450198"],"abstract":["The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries' leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing."],"journal":"Int J Antimicrob Agents","authors":["Tripathy, Satyajit","Dassarma, Barsha","Roy, Somenath","Chabalala, Hlupheka","Matsabisa, Motlalepula Gilbert"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijantimicag.2020.106028","keywords":["covid-19","chloroquine","hydroxychloroquine","pandemic","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667785213921460225,"score":239.68048},{"pmid":32430286,"title":"The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?","text":["The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?","The anti-malarial drugs chloroquine (CQ) and primarily the less toxic hydroxychloroquine (HCQ) are currently used to treat autoimmune diseases for their immunomodulatory and anti-thrombotic properties. They have also been proposed for the treatment of several viral infections, due to their anti-viral effects in cell cultures and animal models, and, currently, for the treatment of coronavirus disease 2019 (COVID-19), the pandemic severe acute respiratory syndrome caused by coronavirus 2 (Sars-Cov-2) infection that is spreading all over the world. Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease. Here we review what is currently known on the mechanisms of action of CQ and HCQ as anti-viral, anti-inflammatory and anti-thrombotic drugs and discuss the up-to-date experimental evidence on the potential mechanisms of action of CQ/HCQ in Sars-Cov2 infection and the current clinical knowledge on their efficacy in the treatment of COVID-19 patients. Given the role of iron in several human viral infections, we also propose a different insight into a number of CQ and HCQ pharmacological effects, suggesting a potential involvement of iron homeostasis in Sars-Cov-2 infection and COVID-19 clinical course.","Pharmacol Res","Quiros Roldan, Eugenia","Biasiotto, Giorgio","Magro, Paola","Zanella, Isabella","32430286"],"abstract":["The anti-malarial drugs chloroquine (CQ) and primarily the less toxic hydroxychloroquine (HCQ) are currently used to treat autoimmune diseases for their immunomodulatory and anti-thrombotic properties. They have also been proposed for the treatment of several viral infections, due to their anti-viral effects in cell cultures and animal models, and, currently, for the treatment of coronavirus disease 2019 (COVID-19), the pandemic severe acute respiratory syndrome caused by coronavirus 2 (Sars-Cov-2) infection that is spreading all over the world. Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease. Here we review what is currently known on the mechanisms of action of CQ and HCQ as anti-viral, anti-inflammatory and anti-thrombotic drugs and discuss the up-to-date experimental evidence on the potential mechanisms of action of CQ/HCQ in Sars-Cov2 infection and the current clinical knowledge on their efficacy in the treatment of COVID-19 patients. Given the role of iron in several human viral infections, we also propose a different insight into a number of CQ and HCQ pharmacological effects, suggesting a potential involvement of iron homeostasis in Sars-Cov-2 infection and COVID-19 clinical course."],"journal":"Pharmacol Res","authors":["Quiros Roldan, Eugenia","Biasiotto, Giorgio","Magro, Paola","Zanella, Isabella"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430286","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104904","keywords":["covid-19","chloroquine/hydroxychloroquine","inflammation","iron","sars-cov-2","thrombosis"],"locations":["optimal"],"e_drugs":["Chloroquine","4-aminoquinoline","Hydroxychloroquine","Iron"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288150331392,"score":223.09079},{"pmid":32324363,"title":"[Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].","text":["[Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].","Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis. The authors conclude the proarrhytmic effects of hydroxychloroquine and the most important signs of drug-induced long QT syndrome. This article is especially relevant and timely due to the more frequent (currently not evidence-based) use of the drug during the 2019-2020 coronavirus pandemic. Orv Hetil. 2020; 161(17): 689-691.","Orv Hetil","Tomcsanyi, Janos","Tomcsanyi, Kristof","32324363"],"abstract":["Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis. The authors conclude the proarrhytmic effects of hydroxychloroquine and the most important signs of drug-induced long QT syndrome. This article is especially relevant and timely due to the more frequent (currently not evidence-based) use of the drug during the 2019-2020 coronavirus pandemic. Orv Hetil. 2020; 161(17): 689-691."],"journal":"Orv Hetil","authors":["Tomcsanyi, Janos","Tomcsanyi, Kristof"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324363","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31817","keywords":["hidroxiklorokin","hosszu-qt-szindroma","hydroxychloroquine","long qt syndrome","proarrhythmia","proarrhythmic effect","syncope","torsade de pointes kamrai tachycardia","torsade de pointes ventricular tachycardia"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493850484737,"score":209.90651},{"pmid":32456286,"title":"Antiviral Effects of Hydroxychloroquine and Type I Interferon on In Vitro Fatal Feline Coronavirus Infection.","text":["Antiviral Effects of Hydroxychloroquine and Type I Interferon on In Vitro Fatal Feline Coronavirus Infection.","Feline infectious peritonitis (FIP) is a viral disease with a high morbidity and mortality by the FIP virus (FIPV, virulent feline coronavirus). Several antiviral drugs for FIP have been identified, but many of these are expensive and not available in veterinary medicine. Hydroxychloroquine (HCQ) is a drug approved by several countries to treat malaria and immune-mediated diseases in humans, and its antiviral effects on other viral infections (e.g., SARS-CoV-2, dengue virus) have been confirmed. We investigated whether HCQ in association with interferon-omega (IFN-omega) is effective for FIPV in vitro. A total of 100 muM of HCQ significantly inhibited the replication of types I and II FIPV. Interestingly, the combination of 100 muM of HCQ and 10(4) U/mL of recombinant feline IFN-omega (rfIFN-omega, veterinary registered drug) increased its antiviral activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-omega are applicable for treatment of FIP. Further clinical studies are needed to verify the combination of HCQ and rIFN-omega will be effective and safe treatment for cats with FIP.","Viruses","Takano, Tomomi","Satoh, Kumi","Doki, Tomoyoshi","Tanabe, Taishi","Hohdatsu, Tsutomu","32456286"],"abstract":["Feline infectious peritonitis (FIP) is a viral disease with a high morbidity and mortality by the FIP virus (FIPV, virulent feline coronavirus). Several antiviral drugs for FIP have been identified, but many of these are expensive and not available in veterinary medicine. Hydroxychloroquine (HCQ) is a drug approved by several countries to treat malaria and immune-mediated diseases in humans, and its antiviral effects on other viral infections (e.g., SARS-CoV-2, dengue virus) have been confirmed. We investigated whether HCQ in association with interferon-omega (IFN-omega) is effective for FIPV in vitro. A total of 100 muM of HCQ significantly inhibited the replication of types I and II FIPV. Interestingly, the combination of 100 muM of HCQ and 10(4) U/mL of recombinant feline IFN-omega (rfIFN-omega, veterinary registered drug) increased its antiviral activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-omega are applicable for treatment of FIP. Further clinical studies are needed to verify the combination of HCQ and rIFN-omega will be effective and safe treatment for cats with FIP."],"journal":"Viruses","authors":["Takano, Tomomi","Satoh, Kumi","Doki, Tomoyoshi","Tanabe, Taishi","Hohdatsu, Tsutomu"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456286","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/v12050576","keywords":["feline coronavirus","feline infectious peritonitis","hydroxychloroquine","interferon"],"locations":["Feline","Hydroxychloroquine"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667967699063406592,"score":204.52385}]}